Physician profile
David E Reinhard
NPI 1508843095
$3,304.14
in general payments reported to CMS, 2019-2025
29 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $346 · 2021: $631 · 2022: $793 · 2023: $372 · 2024: $239 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $456.64 | 2021-2025 | |
| Novo Nordisk INC | $394.56 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.93 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $270.39 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $253.94 | 2019-2023 | Steglatro, Steglujan, Belsomra |
| Sanofi-Aventis U.S. LLC | $240.31 | 2019-2022 | |
| Pfizer INC. | $235.28 | 2019-2022 | |
| Amgen INC. | $196.74 | 2019-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $171.52 | 2019-2023 | Spravato |
| Exact Sciences Corporation | $126.95 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $92.63 | 2019-2023 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $75.42 | 2021-2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $73.64 | 2020-2023 | Fasenra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.42 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.75 | 2024-2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $47.08 | 2021 | |
| Abbott Laboratories | $42.11 | 2023-2024 | Freestyle Libre 3 |
| Allergan, INC. | $37.75 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $33.46 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $30.50 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $21.77 | 2024 | Voquezna |
| Astellas Pharma US INC | $19.49 | 2022 | |
| Mylan Specialty L.P. | $18.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.99 | 2020 | |
| Axsome Therapeutics, INC. | $13.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.43 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $12.57 | 2019 | |
| Genentech USA, INC. | $12.44 | 2020 | |
| Amarin Pharma, INC. | $12.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reinhard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.